La tirzepatida es un agonista dual del receptor de GIP (polipptido insulinotrpico dependiente de glucosa) y GLP-1 (pptido similar al glucagn-1) aprobado por la FDA para el tratamiento de la diabetes tipo 2 y el control del peso
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, Sinha RR
Psychobiotics highlight the pathways to happiness
Gillian M
However, taking periodic breaks (2-4 weeks off after each cycle) may help maintain effectiveness and prevent potential tolerance